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Abstract.
Background: In Parkinson’s disease (PD), there is heterogeneity in the clinical presentation and underlying biology. Research
on PD subtypes aims to understand this heterogeneity with potential contribution for the knowledge of disease pathophysi-
ology, natural history and therapeutic development. There have been many studies of PD subtypes but their impact remains
unclear with limited application in research or clinical practice.
Objective: To critically evaluate PD subtyping systems.
Methods: We conducted a systematic review of PD subtypes, assessing the characteristics of the studies reporting a subtyping
system for the first time. We completed a critical appraisal of their methodologic quality and clinical applicability using
standardized checklists.
Results: We included 38 studies. The majority were cross-sectional (n = 26, 68.4%), used a data-driven approach (n = 25,
65.8%), and non-clinical biomarkers were rarely used (n = 5, 13.1%). Motor characteristics were the domain most commonly
reported to differentiate PD subtypes. Most of the studies did not achieve the top rating across items of a Methodologic
Quality checklist. In a Clinical Applicability Checklist, the clinical importance of differences between subtypes, potential
treatment implications and applicability to the general population were rated poorly, and subtype stability over time and
prognostic value were largely unknown.
Conclusion: Subtyping studies undertaken to date have significant methodologic shortcomings and most have questionable
clinical applicability and unknown biological relevance. The clinical and biological signature of PD may be unique to the
individual, rendering PD resistant to meaningful cluster solutions. New approaches that acknowledge the individual-level
heterogeneity and that are more aligned with personalized medicine are needed.
Keywords: Parkinson’s disease, heterogeneity, subtypes
INTRODUCTION
Parkinson’s disease (PD) is known for its hetero-
geneity in terms of both clinical practice and under-
lying biology [1]. One approach to understanding the
variability present in PD is to identify subtypes; that
is, to define groups of patients with a set of differ-
entiating features at a clinical, biological, genetic or
pathological level.
Research on PD subtypes has garnered consider-
able attention for its potential to elucidate the disease
pathophysiology and natural history and ultimately,
guide therapeutic development. However, the impact
of PD subtype identification on our understanding
of PD pathogenesis or clinical treatment remains
unclear with limited application in research or clinical
practice. Methodologic heterogeneity, lack of repro-
ducibility, poor prognostic value, and limited clinical
applicability are among the possible reasons for the
reduced impact of PD subtypes [2].
The Task Force for PD Subtypes was convened
in 2018 by the International Parkinson’s disease and
Movement Disorders Society (MDS) to critically
appraise the available PD subtyping studies and to
provide guidance for the design and conduct of future
studies on PD subtypes. In this systematic review
of PD subtypes, we evaluate both the methodologic
quality and clinical applicability of studies propos-
ing a new subtyping system. Based on these findings,




We searched for PD subtyping studies in PubMed/
MEDLINE using the following search terms: ‘Par-
kinson Disease’[Mesh] AND (‘Subtyp∗’ OR ‘Phe-
notype’[Mesh] OR ‘Phenotyp∗’ OR ‘Biomarkers’
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[Mesh] OR ‘Clinical Feature∗’ OR ‘endopheno-
typ∗’). We defined a PD subtyping study as any
research study conducted with the purpose of divid-
ing PD patients into subtypes, as stated by its authors,
or identified distinct groups of PD patients that were
discussed as possible subtypes. We excluded studies
that focused on a subgroup of PD patients, such as
those with causative or risk-associated genetic vari-
ants. We only included the initial report of a given
PD subtype classification system. The methodologic
quality of each study and the clinical applicabil-
ity of each identified PD subtype system were
evaluated using a standardized approach. Pairs of
reviewers abstracted data from the included stud-
ies, including study design, baseline characteristics,
PD subtyping methodology and results. We assessed
the methodologic quality and clinical applicability
of the included studies using two tools developed for
the current study: a 13-item checklist for Method-
ologic Quality (item score range: 0–2, higher score
being better, see Table 4) and an 11-item checklist for
Clinical Applicability (items rated as Unknown, Lim-
ited/Low, Moderate, and Strong, see Supplementary
Table 1). We compared rating frequencies between
two publication periods (1980–2014 vs. 2015–2019)
and two subtyping methodologic approaches (data-
driven vs. hypothesis-driven) using Fisher’s exact
tests. The definition of publication periods was
pragmatic to allow for a balanced distribution of
included studies into a more recent group (repre-
senting the current state of the field) and older
studies allowing for a sufficient sample size in each
group to test for temporal trends. A detailed descrip-
tion of Methods is provided in the Supplementary
Material.
RESULTS
We identified 51 studies after the initial screen-
ing, of which 13 studies were excluded after full-text
review (Supplementary Figure 1). Of the 38 included
studies, 68.4% were cross-sectional (n = 26) and
84.2% were conducted in a tertiary care center
(n = 32). Across all studies, the mean disease dura-
tion was 59.8 months. Nine studies (23.7%) included
untreated participants exclusively. Commonly used
descriptors of PD patients (e.g., Unified Parkinson’s
Disease Rating Scale scores) were not reported in a
significant number of studies (Table 1).
Table 1
Study design and sample characteristics of included studies
n = 38
STUDY CHARACTERISTICS
Sample size, mean (range) 293 (15–1601)
Setting - N (%)
Single-center 21 (55.3)
Multi-center 15 (39.5)
Not reported 2 (5.2)
Recruitment Source - N (%)
Tertiary care 32 (84.2)
Community-based/Tertiary Care 2 (5.2)
Not reported 4 (10.5)
Design - N (%)
Cross-sectional 26 (68.4)
Longitudinal 12 (31.6)
Subtyping Approach - N (%)
Hypothesis-driven 8 (21.0)
Data-driven 25 (65.8)
Hypothesis- and Data-driven 2 (5.3)
Not reported 3 (7.9)
PD Diagnosis - N (%)
By Neurologist 28 (73.7)
Not specified 10 (26.3)
PD Diagnostic criteria - N (%)
UK Brain Bank Criteria 22 (57.9)
UK Brain Bank Criteria+DAT Scan 1 (2.6)
Other formal criteria 2 (5.2)
No formal criteria/Investigator opinion 7 (18.4)
Not reported 6 (15.8)
SAMPLE CHARACTERISTICS∗
Age, mean (range) 64.9 (57.5–70.6)
Not reported = 5
Male (proportion), mean (range) 62.6 (37.1–66.8)
Not reported = 8
Disease Duration (months), mean (range) 47.4 (6.5–121.9)
Not reported = 8





Not reported 7 (18.4)
∗Means are weighted by study sample size.
Identification and description of reported PD
subtypes
In the 38 included studies, 65.8% (n = 25) used
exclusively a data-driven approach and 21.1% (n = 8)
used exclusively a hypothesis-driven approach, eval-
uating differences between pre-determined groups.
Five studies either used a combined approach
(n = 2) or alternative analytical approaches such as
regression analyses or post-hoc grouping based on
results of the study (n = 1). Most of the data-driven
studies (n = 16/25, 64.0%) used at least three phe-
notypic domains to identify PD subtypes, while
7/8 hypothesis-driven studies used a single domain.
Overall, the motor domain was most frequently used
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Table 2





n = 8 n = 25
Number of phenotypic domains used
for subtyping - N (%)
Single-domain 7 (87.5) 9 (36.0)
Two domains 1 (12.5) -
> = 3 domains 16 (64.0)
Phenotypic domain(s) - N (%)
Demographic 2 (25.0) 8 (32.0)
Motor 3 (37.5) 18 (72.0)
Cognitive 1 (12.5) 17 (68.0)
Emotional 1 (12.5) 17 (68.0)
Autonomic 1 (12.5) 11 (44.0)
Treatment - 3 (12.0)
Non-clinical Biomarkers∗ - 5 (20.0)
∗Imaging (n = 4), biochemical (n = 1)
Statistical approaches
Pre-determined groups 8 (100) -
Hierarchical cluster analysis - 7 (28.0)





Five studies were not included in this analysis for the following rea-
sons: combined hypothesis- and data-driven approach (n = 2) and
other methods (regression analyses, n = 2; subtype criteria defined
post-hoc, n = 1).
for subtyping in both types of studies, followed by
non-motor domains, such as cognitive, emotional or
autonomic, in studies using a data-driven approach,
and the demographic domain (age or sex) in hypo-
thesis-driven studies. Only five studies included
non-clinical biomarkers, all of which adopted a data-
driven approach (Table 2).
From the descriptions of the resulting subtypes,
reviewers identified which specific features dis-
tinguished the groups in a statistically significant
manner. The reviewed PD subtypes were found to
have on average three statistically significant distinc-
tive features between subtypes (mean = 3.3, range:
0–9). Features within the motor domain were the most
commonly reported to differentiate PD subtypes.
Imaging biomarkers were found to be a differenti-
ating feature in three out of four studies that included
this domain (Table 3).
Methodologic quality (Table 4, Supplementary
Table 2)
Most of the studies did not achieve the top rating
across methodologic quality items, with the exception
Table 3
Phenotypic domains discriminating PD subtypes reported in the
included studies. We included both variables initially used to iden-
tify PD subtypes and additional variables found to be statistically
significantly different between subtypes after the identification of
PD subtypes in a study







Other non-motor 5 4.6%
Quality of Life/Functional ability 6 5.4%
Time-defined measures∗ 9 8.2%
Non-clinical biomarkers∗∗ 3 2.7%
∗Examples: disease duration, UPDRS/disease duration. ∗∗Neuro-
imaging only.
of the items ‘diagnostic methods’ and ‘variables com-
pared between subtypes’. Statistical methods were
difficult to evaluate. Emerging themes were recruit-
ment from clinics rather than community sources, the
lack of reporting of specific methods of clustering,
lack of specification of how the number of clusters
was determined, lack of justification of sample size,
lack of adjustment for multiple comparisons when
comparing features of the clusters, and lack of adjust-
ment for or exploration in the report of the impact of
fundamental baseline characteristics such as disease
duration [3].
The four studies with the best quality ratings [4–
7] were multi-center, longitudinal, data-driven stud-
ies published after 2016. These studies used more
than one clinical domain (motor and non-motor)
and only one study used additional CSF and neu-
roimaging biomarker data [7]. Two of the four studies
used a homogeneous PD population in terms of
stage/disease duration and conducted validation of
the identified PD subtypes [4, 5]. In spite of incor-
porating similar clinical domains represented in the
cluster analyses, there were no clear similarities
among subtypes described in these two studies [4,
5]. Only one study developed an algorithm to classify
individual participants into a PD subtype [4] and only
one of these studies assessed the temporal stability of
PD subtypes [6].
Compared with hypothesis-driven studies, data-
driven studies more frequently used multi-center
data collection (p = 0.04) and more than one clinical
domain or biomarker (p = 0.003). We did not identify
significant differences between the groups of stud-
ies published before or after 2015 (Supplementary
Table 4).
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Table 4
Item score distributions in the 13-item Methodologic Quality tool of included subtyping studies using a data-driven or hypothesis-driven
approach
Item Score rating Hypothesis- Data- p
driven driven
(n = 8) (n = 25)
Disease stages/duration (study population) 0 = mixture of stages/disease duration at baseline
or not reported
5 (62.5) 18 (72) 0.67
1 = homogeneous disease stage/duration 3 (37.5) 7 (28)
Study setting (representativeness) 0 = single-center or not reported 7 (87.5) 10 (40) 0.04
1 = multi-center 1 (12.5) 15 (60)
Recruitment source (generalizability) 0 = clinic-based or not reported 8 (100) 25 (100) 1
1 = community or population-based 0 (0) 0 (0)
Diagnostic methods 0 = not described or 1 or 2 not applicable 2 (25) 1 (4) 0.04
1 = Use of formal diagnostic criteria or diagnosis
by an expert neurologist
6 (75) 24 (96)
2 = postmortem diagnosis 0 (0) 0 (0)
Sampling method 0 = convenience or not reported 5 (62.5) 21 (84) 0.32
1 = consecutive or random 3 (37.5) 4 (16)
Comprehensiveness of data used for subtyping
(subtype definition)
0 = single clinical or biomarker domain 8 (100) 9 (36) 0.003
1 = > 1 clinical domains or biomarkers 0 (0) 16 (64)
Variables compared between subtypes (post hoc) 0 = not done 0 (0) 2 (8) 1
1 = single clinical domain or biomarker 0 (0) 0 (0)
2 = > 1 clinical domains or biomarkers 8 (100) 23 (92)
Statistical methods used for subtyping 0 = low quality 4 (50) 4 (16) 0.11
1 = intermediate quality 3 (37.5) 10 (40)
2 = high quality 1 (12.5) 11 (44)
Longitudinal follow-up 0 = none (cross-sectional) or longitudinal < 1
year
6 (75) 17 (68) 0.68
1 = short-term (1–3 years) OR longer-term but
< 3 time-points
2 (25) 4 (16)
2 = longer-term (> 3 year) AND > = 3 time-points 0 (0) 4 (16)
Completeness of follow-up 0 = cross-sectional or ≤ 50% complete or not
reported
7 (87.5) 20 (80) 1
1 = 50–75% complete 1 (12.5) 2 (8)
2 = > 75 % complete 0 (0) 3 (12)
Subtype stability 0 = not assessed 8 (100) 23 (92) 1
1 = assessed 0 (0) 2 (8)
Algorithm for classifying individual patients 0 = not provided 0 (0) 24 (96) < 0.001
1 = provided 8 (100) 1 (4)
Validation (internal or external) 0 = not assessed 8 (100) 19 (76) 0.57
1 = use of a test set from the same population 0 (0) 4 (16)
2 = validation in an external population 0 (0) 2 (8)
Clinical applicability (Supplementary Table 3,
Supplementary Figure 2)
Overall, items reflecting the clinical importance
of differences between subtypes, potential treatment
implications and applicability to the general popu-
lation of PD patients were rated poorly for most
studies. Subtype stability over time and prognos-
tic value were largely unknown due to the paucity
of longitudinal studies. Compared with hypothesis-
driven subtypes, data-driven subtyping was seen as
burdensome and time-consuming (p = 0.01). Both
data-driven and hypothesis-driven subtyping were
usually rated as inexpensive. There were no clear
differences between newer and older studies for the
different items of the Clinical Applicability tool (Sup-
plementary Figure 3)
DISCUSSION
Our systematic review has revealed gaps in the field
and highlighted the limitations of current approaches
to PD subtyping. It thereby informs recommenda-
tions on the methodology of future subtyping studies
and suggests alternative directions. Recommenda-
tions are highlighted in italics.
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Research methodology: Can we do better?
Quality ratings for subtyping studies revealed clear
areas for improvement. More extensive use of longi-
tudinal data is critical for an understanding of the
stability of proposed subtypes, and their prognostic
value. The use of longitudinal data to define or eval-
uate subtypes does appear to be more common in the
last 5 years [4–8], making use of large, publicly avail-
able cohorts [4, 9]. To our knowledge, only one study
has used longitudinal profiling as the basis for defin-
ing subtypes [7], incorporating data on the evolution
of clinical or biological features across time into the
definition of subtypes. Alternatively, serial cluster
analyses could provide data about the stability of pro-
posed subtypes and the influence of disease duration
on their characteristics. Such approaches could pro-
vide additional prognostic value, using information
about the early evolution of disease to inform later
prognosis or underlying biology.
An area for future study is incorporating the pro-
dromal phase of PD, which presents the opportunity
to start defining subtypes of the disease earlier in
the pathological process, which may provide new
insights. A better understanding of the starting point
and initial progression may better predict the course
and subsequent clinical progression and offer the
opportunity for an early target-specific therapeutic
development.
A recurring reporting flaw was failure to describe
statistical methods in detail. This issue may become
more frequent as machine learning will probably play
an important role in complex (hypothesis-free) analy-
ses, particularly as the scope of available data expands
[10]. It is important that the clustering method that
is used is explicitly described in sufficient detail to
facilitate independent replication and pursuit of sub-
sequent hypothesis-driven studies [11].
Data-driven analyses were rarely replicated in a
separate cohort. This is likely related to the fact that
similar data are not always available on different
cohorts and cohorts differ in their eligibility criteria
(and assessments), resulting in fundamentally differ-
ent characteristics of patients. However, it was also
rare for studies to use internal replication techniques
such as resampling. Internal or external replication
attempts are important to assess the general applica-
bility of suggested subtyping methods.
It was noted that the domains covered in subtyp-
ing studies and the instruments used were variable,
limiting the value of comparisons across studies.
Consensus moving forward as to the methodologic
approach and the key core set of domains would be
helpful for the field.
Subtyping by design
Possible uses of subtyping include clinical prog-
nostication or identifying biological subtypes that
predict therapeutic response to symptomatic (tar-
geting convergent mechanisms, such as dopamine
deficiency) or disease-modifying interventions (tar-
geting divergent biological mechanisms, such as
mitochondrial dysfunction). Different study designs
may serve different purposes.
Design of subtyping studies fell into two main
categories: 1) data-driven analyses and 2) hypothe-
sis-driven analyses based on pre-determined groups.
Hypothesis-driven studies were usually single
domain analyses of a clinical or demographic char-
acteristic such as age of onset, or tremor-dominant
vs. akinetic-rigid (‘motor subtyping’), and this was
felt to be an inferior approach compared with consid-
ering multiple domains of data in a hypothesis-free
subtyping exercise. However, it may be that focused
hypothesis-driven evaluation of pre-defined groups
is important for answering specific research ques-
tions, and this approach may have more potential
for direct neurobiological mapping with concomitant
biomarker measurement. For example, this approach
has successfully identified biological differences
between individuals based on motor phenotype [12,
13]. Findings from data-driven studies should be sim-
ilarly used for hypothesis-driven studies to define
the clinical applicability and/or biological underpin-
nings of the described subtypes. Importantly, clinical
applicability may not be a relevant objective of some
subtyping efforts.
Subtyping studies have usually enrolled individ-
uals at various points in the disease course and
analyzed the cohort without stratification on disease
duration or stage. This approach makes it more dif-
ficult to describe phenotypic variability at specific
phases of the disease. In addition, patients may be
misclassified if individuals at different disease dura-
tions are included without taking the phenotypic
changes with disease duration into account. Certain
aspects such as motor phenotype tend to be more
heterogeneous early in the disease process, converg-
ing to a common phenotype toward the end [14, 15].
Thus, subtyping exercises may produce very differ-
ent results depending on the distribution of disease
duration or stage at which the subtyping is per-
formed. We would recommend subtyping based on
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longitudinal data starting from a defined disease dura-
tion or milestone in order to maximize interpretability
and minimize these confounding issues.
The included studies were all clinic-based, rather
than recruiting from community sources. This may be
a more or less important source of bias depending on
the purpose of the subtyping; individuals from these
two sources are unlikely to differ in the underlying
biology of the disease but may well differ in clinical
severity and prognosis. A community-based sample
would be more generalizable.
What is the clinical and biological relevance of
subtypes?
The clinical importance of the differences between
the defined subtypes was deemed moderate or less for
the vast majority of studies. Whether or not the pro-
posed subtypes are stable, or become more or less
different over time, could not be evaluated in this
review for most classification systems since longi-
tudinal differences were not assessed in the original
descriptions of the subtypes. These limitations raise
important questions about the clinical relevance of
subtypes defined to date, with the caveat that we have
not evaluated the literature following up the initial
descriptions of the subtypes. We are aware of many
studies evaluating subtypes defined by motor fea-
tures contrasting tremor-dominant (TD) with other
phenotypes. Some have looked at the prognostic
implications of these subtypes [16, 17] and several
studies have demonstrated that a high proportion
of individuals with the TD phenotype will switch
to a PIGD phenotype over time [14, 15, 18]. An
adverse cognitive prognosis and prominent cortical
Lewy body involvement associated with the non-
tremor dominant phenotypes confirms the prognostic
relevance of those subtypes [19]. Recently, there has
also been an independent examination of the clinical
and pathological evolution of data-driven subtypes
as defined by an earlier cohort study [4]. Important
differences in time to important clinical milestones
between the subgroups were shown in a separate
cohort, supporting the clinical importance of those
subtypes [20]. Unfortunately, such studies are rare
and we encourage such prognostic studies to clarify
the clinical relevance of any described subtypes.
The relationship between clinically-based sub-
types and the underlying biology of disease has rarely
been assessed to date. Several studies have evalu-
ated the biological characteristics of TD and PIGD
phenotypes, finding differences in CSF composition
(alpha-synuclein [21], 5-hydroxyindoleacetic acid,
glycine [12]) and degree of cardiac sympathetic
denervation, for example [21]. We are aware of
only two studies evaluating the biomarker pro-
file of data-driven subtypes, identifying a possibly
pro-inflammatory profile [9] and an “Alzheimer’s-
like” profile of low CSF amyloid- and high tau
[4] associated with a severe motor and non-motor
disease subtype. In the absence of validated non-
clinical biomarkers of PD progression, the value
of clinically-based subtyping to help direct disease-
modifying therapies targeting specific biological
processes is unknown. Establishing the relationship
between clinically-based subtypes and biomarkers of
the underlying disease biology is an important goal,
as it may inform the development of subtype-targeted
therapies.
We also found that there was little inclusion of
biomarkers in studies defining PD subtypes. This
has the same implications as mentioned above, limit-
ing our understanding of the biological relevance of
subtypes. We further recommend biologically-based
subtyping studies.
Can subtyping be incorporated into clinical
practice?
Clinical applicability may not be the goal of all
subtyping efforts, such as those seeking to under-
stand heterogeneity in the underlying biology of the
disease. Therefore, clinical applicability may not be
a relevant criterion on which to rate some studies.
Nonetheless, it is relevant to note that our expert
group had reservations about the feasibility of sub-
typing as part of routine clinical practice with the
tools currently available. That conclusion was driven
by 1) the extra time required to assign individuals
to subtypes using multi-domain data, beyond that
allocated to usual clinic visits and 2) the lack of an
algorithm to classify individual patients. An advan-
tage of hypothesis-based single-domain subtyping
systems is the availability of a clear and simple algo-
rithm to assign individuals to groups, facilitating both
replication of findings in different cohorts [20] and
application in a clinical setting. It is rare that data-
driven studies use their results to derive an algorithm
for assigning individuals to subtypes, although there
is at least one exception [4, 20]. Even if feasible, the
applicability of the results to individuals is unclear
given that subtyping has so far been studied only at the
group level. Studies examining the prognostic or bio-
logical relevance at the individual level are needed to
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establish clinical applicability. Furthermore, simple
classification systems based on a manageable num-
ber of variables would be a prerequisite for adoption
by the clinical community; however, simplicity is at
odds with the fact that PD is etiologically and phe-
notypically complex, and being a disease associated
with aging, subject to multiple intersecting biological
processes [22] and co-existing medical comorbidities
[23] that can intervene to influence the phenotype at
any point in the disease process.
Is subtyping possible?
Subtyping studies undertaken to date have signifi-
cant methodologic shortcomings and most have ques-
tionable clinical applicability. Many studies were
limited in terms of the clinical domains consid-
ered to define subtypes, and measures used in data-
driven analyses were highly heterogeneous, resulting
in highly variable findings. Even the two data-driven
studies receiving the highest quality ratings and
incorporating variables from comparable domains
showed limited similarity of the subtypes they found.
Despite decades of subtyping research, there has been
minimal incorporation of subtype information into
research or formal incorporation in clinical practice.
These observations call into question the feasibil-
ity of clinical subtyping and suggest that alternative
approaches to describing and understanding the het-
erogeneity of PD are needed.
As described above, PD is biologically complex,
a result of many intersecting processes that vary
from person to person. Blood and cerebrospinal
fluid parameters associated with PD show high inter-
individual heterogeneity, requiring combinations of
multiple markers to optimize diagnostic accuracy
[24]. Variable co-pathology adds to the heterogene-
ity [25]. Several ‘causative’ genes, none completely
penetrant, and a vast array of susceptibility genes gov-
erning widely-varying metabolic processes have been
elucidated [26]. RNA expression studies demonstrate
the complex genetic and biologic heterogeneity of
PD [27]. It is a testament to this complexity that
metabolomics are now being used to measure the
downstream effects of a vast array of contributory
genetic, environmental and physiological processes
[28]. As a result, the phenotype of PD is unique to an
individual. Given these challenges, it seems unlikely
that a purely clinically-based subtyping system mea-
suring early disease features and seeking to place
patients into a small number of categories will be
able to adequately describe PD heterogeneity in order
to provide accurate pathophysiological or prognostic
insights. It remains to be seen whether this can be
improved by the discovery of better biomarkers but
underlying biological heterogeneity may also render
biomarker-based subtyping resistant to meaningful
cluster solutions. This idea is not new; it has been
previously proposed that PD is not one disease but
rather a syndrome representing the manifestations of
multiple or even an infinite number of underlying
diseases [29].
Contemporary medicine is increasingly promoting
personalized treatment, including in Parkinson’s dis-
ease, with a focus on the individual [30]. To date,
subtyping places individuals in groups with simi-
lar but not identical features. This may represent
an important step toward identifying individuals that
can respond preferentially to certain treatments but
by virtue of placing individuals within a group will
inevitably fall short of the truly ‘personal’ goal.
Although perhaps more challenging, modern com-
putational techniques are increasingly allowing us to
manage vast amounts of data and may soon allow
us to take full advantage of the information available
in the heterogeneity to describe individuals without
the need for group-level subtyping. Many of the rec-
ommendations outlined above could apply to future
studies where the unit of measure is the individual’s
disease fingerprint rather than the group pheno-
type. Granted, such an individual approach poses
financial and logistical challenges when it comes
to clinical trials which will have to be overcome.
Nonetheless, having reviewed the existing literature
on subtyping and explored the methodologic pitfalls
and challenges associated with performing the opti-
mal subtyping studies described above, it is time
to re-evaluate our approach to understanding and
describing PD heterogeneity.
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